Lee Jie-Jen

Lee Jie-Jen


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
TJThanasekaran Jayakumar
Thanasekaran Jayakumar
CHCheng-Ying Hsieh
Cheng-Ying Hsieh
LJLee Jie-Jen
Lee Jie-Jen
Joen-Rong SheuJoen-Rong Sheu
Joen-Rong Sheu
Andrographis paniculata(Burm. F) Nees, generally known as “king of bitters,” is an herbaceous plant in the family Acanthaceae. In China, India, Thailand, and Malaysia, this plant has been widely used for treating sore throat, flu, and upper respiratory tract infections. Andrographolide, a major bioactive chemical constituent of the plant, has shown anticancer potential in various investigations. Andrographolide and its derivatives have anti-inflammatory effects in experimental models asthma, stroke, and arthritis. In recent years, pharmaceutical chemists have synthesized numerous andrographolide derivatives, which exhibit essential pharmacological activities such as those that are anti-inflammatory, antibacterial, antitumor, antidiabetic, anti-HIV, antifeedant, and antiviral. However, what is noteworthy about this paper is summarizing the effects of andrographolide against cardiovascular disease, platelet activation, infertility, and NF-κB activation. Therefore, this paper is intended to provide evidence reported in relevant literature on qualitative research to assist scientists in isolating and characterizing bioactive compounds.

1 January 2014 in The Scientific World Journal
Verified
Journal Article
Open access
PDF file
YLYe-Ming Lee
Ye-Ming Lee
CCChiu-Yun Chang
Chiu-Yun Chang
TYTing-Lin Yen
Ting-Lin Yen
PGPitchairaj Geraldine
Pitchairaj Geraldine
CLChang-Chou Lan
Chang-Chou Lan
LJLee Jie-Jen
Lee Jie-Jen
In this study, the neuroprotective effect of an extract ofAntrodia camphorata(A. camphorata), a fungus commonly used in Chinese folk medicine for treatment of viral hepatitis and cancer, alone or in combination with aspirin was investigated in a rat embolic stroke model. An ischemic stroke was induced in rats by a selective occlusion of the middle cerebral artery (MCA) with whole blood clots and then orally treated withA. camphorata(0.25 and 0.75 g/kg/day) alone and combined with aspirin (5 mg/kg/day). Sixty days later, the brains were removed, sectioned, and stained with triphenyltetrazolium chloride and analysed by a commercial image processing software program. Brain infarct volume, neurobehavioral score, cerebral blood perfusion, and subarachnoid and intracerebral hemorrhage incidence were perceived. In addition, potential bleeding side effect of the combinative therapy was assessed by measuring hemoglobin (Hb) content during intracerebral hemorrhage and gastric bleeding, prothrombin time (PT), and occlusion time (OT) after oral administration. Posttreatment with high doseA. camphoratasignificantly reduced infarct volume and improved neurobehavioral score (P< 0.05). SinceA. camphorataalone or with aspirin did not alter the Hb level, this treatment is safe and does not cause hemorrhagic incident. Remarkably, the combination ofA. camphorataand aspirin did not show a significant effect on the bleeding time, PT and OT increase suggesting thatA. camphoratamay have the neuroprotective effect without the prolongation of bleeding time or coagulation time. From these observations, we suggest that combinative therapy ofA. camphorataand aspirin might offer enhanced neuroprotective efficacies without increasing side effects.

26 November 2025 in Cancers
Verified
Journal Article
Open access
PDF file
JHJiun-Wei Hsu
Jiun-Wei Hsu
YSYing-Wen Su
Ying-Wen Su
CTChung-Hsin Tsai
Chung-Hsin Tsai
CLChi-Chan Lee
Chi-Chan Lee
HYHorng-Woei Yang
Horng-Woei Yang
PYPo Sheng Yang
Po Sheng Yang
Background/Objectives: Chemotherapy-induced adverse events significantly impact cancer treatment outcomes and patient quality of life. Emerging evidence suggests that gut microbiota composition may influence individual susceptibility to chemotherapy toxicity. This study investigated associations between gut microbiome alterations and specific chemotherapy-related adverse events in breast cancer patients undergoing cancer treatment. Methods: We conducted a prospective cohort study of 81 breast cancer patients receiving chemotherapy between May 2018 and October 2022. Gut microbiome composition was analyzed using 16S rRNA sequencing across multiple taxonomic levels. Alpha diversity (Chao1 estimator) and beta diversity (PERMANOVA) analyses were performed to assess microbial richness and community structure. Linear discriminant analysis effect size (LEfSe) identified differentially abundant taxa, with Cohen’s d effect sizes calculated with 95% confidence intervals and false discovery rate correction applied for multiple comparisons. Results: Significant microbiome-toxicity associations were identified across 42 taxa (FDR q < 0.05, effect sizes d = −1.60 to +1.67). Severe anemia demonstrated the strongest associations, with large effect size enrichment of Eubacteriaceae (d = 1.38), Anaerofilum (d = 1.42), and Eubacterium (d = 1.38). Severe neutropenia was characterized by depletion of butyrate-producing bacteria, particularly Eubacterium_hallii_group (d = −1.08). Thrombocytopenia showed dramatic depletion of Eubacterium limosum (53-fold reduction, d = −1.60). Hepatotoxicity (ALT elevation) was associated with depletion of Eubacterium_hallii_group (d = −0.99) and Burkholderia-Caballeronia-Paraburkholderia (d = −1.19). Hand-foot syndrome exhibited significantly elevated microbial diversity with depletion of Lachnospiraceae taxa. Most adverse events showed enrichment rather than depletion patterns, with 54.8% of significant associations demonstrating medium to large effect sizes. Conclusions: Specific gut microbiota signatures associated with distinct chemotherapy-related adverse events, suggesting potential microbiome-based biomarkers for toxicity prediction and personalized cancer treatment strategies.